Originally Posted by ironaddict69
And if VEGF does that and fits through a small needle, show me a study where it says it’s safe and fits through a small needle, I’ll fucking test it for you.
"POEMS syndrome: definitions and long-term outcome
Presented in abstract form at the 41st annual meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
Angela Dispenzieri,
Robert A. Kyle,
Martha Q. Lacy,
S. Vincent Rajkumar,
Terry M. Therneau,
Dirk R. Larson,
Philip R. Greipp,
Thomas E. Witzig,
Rita Basu,
Guillermo A. Suarez,
Rafael Fonseca,
John A. Lust, and
Morie A. Gertz
……….
Pulmonary hypertension, renal failure, thrombotic events, and congestive heart failure were observed and appear to be part of the syndrome. In 18 patients (18%), new disease manifestations developed over time.
…………….
We conclude that the median survival of patients with POEMS syndrome is 165 months, independent of the number of syndrome features, bone lesions, or plasma cells at diagnosis
………………
Preliminary data suggest that vascular endothelial growth factor is an excellent candidate as a pathogenic factor in POEMS29 30; it induces a rapid and reversible increase in vascular permeability, is a growth factor for endothelial cells, and is considered important in angiogenesis.27………."
http://bloodjou rnal.hematology … 101/7/2496.full
Ophthalmology. 1996 Nov;103(11):1820-8.
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate.
http://www.ncbi … /pubmed/8942877
Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate.
http://www.ncbi … /pubmed/8694732
Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit.
http://www.ncbi … pubmed/11402391
Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates.
http://www.ncbi … /pubmed/9227268
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
Abstract
Multiple myeloma (MM) remains incurable, with a median survival of 3 to 4 years. This study shows direct effects of vascular endothelial growth factor (VEGF) upon MM and plasma cell leukemia (PCL) cells. The results indicate that VEGF triggers tumor cell proliferation via a protein kinase C (PKC)–independent Raf-1–MEK–extracellular signal-regulated protein kinase pathway, and migration via a PKC-dependent pathway. These observations provide the framework for novel therapeutic strategies targeting VEGF signaling cascades in MM.
http://bloodjou rnal.hematology … t/98/2/428.long